Slmnerap Forty-one patients with advanced breast cancer were gven carboplatin and vinorelbine as secondline therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxcicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
Although antracycline-including chemotherapy induces responses in 50-70% of patients with advanced breast cancer, cure is never achieved. Therefore, most patients require second-line treatment whose overall response rate does not exceed 30%, with no definite impact on survival (Henderson, 1991) .
The identification of new antiproliferative agents which lack cross-resistance with the drugs commonly used as firstline therapy continues to be a major area of research (Lippman, 1993 ). Carboplatin, a cisplatin analogue that is significantly less nephrotoxic and neurotoxic than cisplatin itself (O'Brien et al., 1993) , has attractive features as a drug for the treatment of breast cancer because it is not associated with serious organ toxicities, apart from bone marrow suppression. Relatively few phase II studies of carboplatim in advanced breast cancer have been published; in all of them a relationship between activity and lack of previous treatment has been reported (Kolaric and Vukas, 1991; Martin et al., 1992) .
Vinorelbine (VRL, Navelbine; Pierre Fabre Medicanment, Boulogne, France) is a new semisynthetic vinca alkaloid that differs from the others by a substitution that affects the catharanthine moiety and not the vindoline moiety of the molecule (Potier, 1989) . Several phase II studies of singleagent VRL as first-line treatment in advanced breast cancer have been conducted (Canobbio et al., 1989; Lluch et al.. 1992; Fumoleou et al., 1993; Romero et al., 1994; Twelves et al., 1994) , with response rates ranging from 41% to 60%, good tolerance, minor neurotoxicity and rapidly reversible leucopenia. Furthermore, synergy and good tolerance have been observed when vinorelbine is used in combination with platinum compounds (Cros. 1989; Crawford and O'Rourke, 1994) .
We report our experience with a combination of carboplatin and vinorelbine in 41 pretreated patients with advanced breast cancer.
Patients and methods
Patients with advanced breast cancer who had progressed after first line anthracycine-based chemotherapy entered the study. A normal initial blood count (leucocyte >4000 ml-', platelets > 100 000 ml-') was required. (Fumoleau et al., 1993 ) was a quite frequent toxic effect; VRL administration in 125 ml of normal saline over 20 min substantially reduced its idence in the later patients. One patient had a pulmonary embolus after the first course, but its association with treatment is questionable. Toxic effects are smmarised in Table Ill. Despite significant improvements in medical treatment in the last 20 years, metastatic breast cancer is still considered to be an incurable disease. While novel biological therapeutic strategies targeted to factors spefically involved in tumour progression and metastasis are being developed (Lippman, 1993) , investigational efforts are presendy directed to the identification of new active agents with a higher therapeutic index.
Carboplatin has attractive features as a drug for the treatment of advanced breast cancer, because of its significntly lower nephrotoxicity and neurotoxicity compared with the parent compound. However, in the phase H studies of carboplatin in advanced breast cancer published so far, activity has been demonstrated mainly in untreated patients (Kolaric and Vukas, 1991; Martin et al., 1992) . Vinorelbine is a novel vinca alkaloid (Potier et al., 1989) that is attractive because of the possible lack of cross-resistance with other drugs which are active against breast cancer (Henderson, 1991) and because of its low neurotoxicity, which is presumably related to its selctive affinity for mitotic tubulin and tubulinassociated proteins (Potier et al., 1989) , with relative sparing of axonal microtubuks (Fellons et al., 1989) .
In our study 17 35% in 34 patients with metastatic breast cancer refractory to first-line chemotherapy using a combination of vinorelbn (30mgm 2 every 3 weeks) and mitomycin C (15mgm-2 every 6 weeks). To date, only one study has been pubfished in which carboplatin has been evaluated, combined with etoposide, in patients with pretreated metastatic breast cancer. This combination resulted in a very low partial response rate (13%), which caused the early interruption of the trial at 23 patients (Barker et al., 1993) .
We believe that the results of our study justify the use of our combination in the salvage treatment of advanced breast cancer, although quality of life, which is to be considered an important end point in such trials (Porzsolt and Tannock, 1993) , should be more properly a
We beieve that some important points need to be clarified in order to improve treatment results further:
(1) The best dosage and schedule of administration of vinorelbine has to be identified; in particular, the hypothesis of the better therapeutic index achieved by the continuous infusion of this cell-cycle phase-specific drug has to be verified (Toussaint et al., 1994) . (2)The possibility of a more correct calculation of carboplatin dosage, according to Calvert (1989) criteria, is to be considered; we are induced to believe that the use of a pharmacokinetically derived carboplatin dose could contribute to improve the therapeutic index of the drug. (3) Given the h incidence of myekosupression as doselmiting toxicity observed with our regImen, ftr investigations into the optmal schedulng of these agents with G-CSF are to be performed in order to eventually allow either further dose escalation or the addition of other active agents to this regi-en.
